title: Short-term effects of bimatoprost in glaucoma patients from an outpatient clinic.
abstract: OBJECTIVE
  A drug utilization trial was performed to investigate acute versus short-term effects after switching or adding bimatoprost in open-angle glaucoma patients over a 3- month observation period.
  
  
  METHODS
  One (1) eye was randomly chosen from 47 glaucomatous patients (abnormal visual field and/or abnormal optic nerve and intraocular pressure (IOP) above 21 mmHg without treatment). Only patients who did not reach the target IOP with their ongoing treatment were recruited in this study. IOP was measured at baseline, after 1 hour, and 2 hours from the first instillation and after 1 week, 1, and 3 months of treatment.
  
  
  RESULTS
  The IOP before bimatoprost administration was 20.16+/-3.6 mmHg (mean+/-standard deviation). There was no statistically significant decrease of IOP after 1 hour (mean IOP, 19.96+/-4.25 mmHg) and after 2 hours (mean IOP, 17.73+/-3.24 mmHg). Statistically significant (p<0.001) decreases after 1 week (mean IOP, 16.48+/-2.9 mmHg), after 1 month (mean IOP, 16.48+/-2.9 mmHg) and after 3 months (mean IOP, 16.15+/-2.7 mmHg) were found.
  
  
  CONCLUSIONS
  The results suggested that bimatroprost had a significant acute effect on IOP in monotherapy, while no significant effect was found when the therapy was switched or added. The effect for primary open-angle glaucoma was very evident. There was no specific side effect attributable to combining bimatoprost with any of the treatments in use.
authors.affiliation: Department of Neurological Sciences, Ophthalmology, Genetic, Clinica Oculistica, University of Genoa, Italy. iester@unige.it
authors.forename: Michele
authors.initials: M
authors.lastname: Iester
authors.forename: Andrea
authors.initials: A
authors.lastname: Perdicchi
authors.forename: Gianmaria
authors.initials: G
authors.lastname: Venturino
authors.forename: Maurizio
authors.initials: M
authors.lastname: Rolando
authors.forename: Carlo E
authors.initials: CE
authors.lastname: Traverso
authors.forename: Elvio
authors.initials: E
authors.lastname: Leonardi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Calabria
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000554:Ambulatory Care Facilities; D000577:Amides; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008055:Lipids / Q000627:therapeutic use*; D008297:Male; D009883:Ophthalmic Solutions
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D000069580:Bimatoprost